39 GHP Q4 2023 the actual effectiveness of a drug. Being able to measure the interactions with real samples not only saves time and money but also provides more physiologically relevant data.” Finally, BI understands that it is important for the company to work alongside customers and partners to ensure that it best adapts to their needs and stays ahead of the market, rather than the alternative – risking losing ground due to a failure to meet demand. Tianwei concludes by diving into how this ongoing mission plays into the company’s future. “BI has been working with its customers and partners to enhance the cell-based binding kinetic measurements and move forward to provide more advanced assay development in drug compound study in label-free, in vitro singlecell analysis.” Company: Biosensing Instrument Inc Name: Tianwei Jing Email: [email protected] Web Address: www.BiosensingUSA.com Address:1007 E Warner Rd, Suite 102, Tempe, Arizona 85284 Telephone:480-491-2777 here’s unprecedented demand for ‘better’, ‘more effective’, ‘more efficient’ in the life-sciences and research spaces, driven by a constant forward momentum to match the pace of competitors and peers alike. In this sphere, Biosensing Instrument Inc has become a truly standout element through a dedication to best practices, understanding that efficacy is the true driver of enduring change and development. Partnering this with an internal culture that rewards and promotes hard work, BI strives for extraordinary success, always. Here Tianwei starts by explaining more of the intricacies behind the company’s offerings and expertise. “BI offers a unique cell-based SPR assay to measure real-time binding kinetics between drug compounds and membrane protein receptors on whole cells in vitro and label-free. BI has been providing measurement tools and services to biotech and pharmaceutical companies to qualify drug candidates and characterise the binding affinity and efficacy of compound molecules with membrane proteins in their native environments. “BI’s cell based SPR assay preserves the integrity of membrane proteins to gain more insights on drug efficacy at natural physiological conditions. The SPRm 200 model, developed with BI’s cell based SPR technology, streamlines the measurement process and enables a simultaneous spatial visualisation of cellular structures (optical microscopy) together with local binding activities mapping (SPR microscopy) of individual cells. As a result, the measured binding data in a label-free, real-time, in vitro are biologically more relevant for the characterisation of drug molecule design and significantly advance the early drug discovery to fight cancer and other diseases.” Let’s touch on the internal culture of the company and how it encourages an ethos of constant betterment and improvement. The experienced management, with Tianwei included in that metric, works diligently to create and nurture a climate of mutual respect, personal integrity, and accountability that, in turn, empowers individuals. “We take great pride in doing our best and delighting our customers. BI has recruited many top-notch scientists and engineers over the last several years,” Tianwei takes a moment to add. As it stands, BI’s strengths lie in how its instruments offer something that competitors cannot. The current prominent paradigm in the industry is to focus on protein-protein interaction and their binding affinity and kinetics. BI’s solution is able to save vital resources when compared to alternative instrument providers. “To do these types of measurements, one must extract and purify the protein first. As cell membrane proteins are difficult to extract and purify from their lipid environment, it is hard to keep them in their native form. SPRm200 enables measuring cell membrane protein interaction at its active site in its native form. It provides a vital insight into Biosensing Instrument Inc (BI) is a global life-science instrument supplier of surface plasmon resonance (SPR) systems that are utilised in the greater pharmaceutical industry and academic research. Following the company’s recognition as the ‘Specialist Medical Instrument Supplier of the Year’ for the USA, we spoke to President and Co-Founder, Tianwei Jing for more insight into the company’s incredible history and drive for innovation. Driving for State-of-the-Art Innovation in Life-Science T 68
RkJQdWJsaXNoZXIy NTY1MjM3